Pomerantz Law Firm Investigates Inspire Medical Systems for Potential Securities Fraud

Investor Alert: Examining Inspire Medical Systems

The Pomerantz Law Firm has announced its investigation into Inspire Medical Systems, Inc. (NYSE: INSP), focusing on potential securities fraud and unlawful business practices that may have occurred within the company’s leadership. This inquiry highlights the need for investors to stay informed and vigilant, particularly in an environment where security breaches are increasingly common.

Overview of the Situation

On August 4, 2025, Inspire Medical released its second quarter financial results, which drew significant attention due to adjusted revenue forecasts that fell short of expectations. The company modified its full-year revenue targets, reducing them from a prior estimate of $940 million - $955 million to a new range of $900 million - $910 million. This significant revision also affected the diluted net income per share, which was adjusted downward from an expected range of $2.20 - $2.30 to just $0.40 - $0.50. The key reason cited for these reduced projections was the slower-than-anticipated progress in launching its next-generation Inspire V neurostimulation system.

As a consequence of this disappointing news, the stock price of Inspire Medical plummeted by $42.04 per share—representing a staggering 32.35% drop—closing at $87.91 on August 5, 2025. This drastic decline has left many investors concerned, prompting the law firm's investigation into whether the actions and disclosures of Inspire's officers and directors were aligned with lawful business practices.

About Pomerantz LLP

Pomerantz LLP is a law firm with a long-standing reputation in corporate and securities litigation, with offices located in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. The firm was established by Abraham L. Pomerantz, a pioneer in the area of securities class actions. For over 85 years, Pomerantz has been at the forefront of fighting for the rights of investors who have suffered from securities fraud and corporate misconduct.

The firm has assisted in recovering substantial damages for its clients and has cultivated an impressive history of favorable outcomes in class action suits. Prospective investors who believe they may have been affected by Inspire's business practices are encouraged to reach out to Pomerantz for support and guidance on how to proceed.

Implications for Investors

The ongoing investigation by Pomerantz LLP could hold significant implications for current and potential investors in Inspire Medical Systems. If evidence of fraud or unethical business conduct is uncovered, it could lead to legal repercussions for the responsible parties and enable affected investors to seek compensation. In such cases, collective action may amplify the voices and rights of those seeking justice in the financial marketplace.

Investors with concerns are advised to closely monitor developments surrounding Inspire Medical Systems and engage with legal professionals to understand their options. The landscape of investment often entails risks, and being informed about corporate governance and compliance is crucial for making prudent investment decisions.

In conclusion, investors of Inspire Medical Systems should stay alert to updates regarding the investigation and ensure they are working with trusted legal resources if they feel adversely affected by recent events. Pomerantz LLP has opened its doors to inquiries and is prepared to assist those navigating this complex situation.

Conclusion

The atmosphere surrounding Inspire Medical Systems may serve as a reminder of the inherent risks in the stock market. With companies attempting to balance innovation and accountability, investors must remain cautious and proactive in advocating for their rights. For additional information or to join the class action, interested parties should reach out directly to Danielle Peyton at Pomerantz LLP.

Contact: